Publication | Closed Access

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Brca1/2 MutationMedicineCancer ManagementGynecologyOlaparib TabletsRelapsed Ovarian CancerPharmacotherapyCancer TreatmentOncologyRadiation OncologyGynecology OncologyEndocrine-related CancerOvarian Cancer